SuperworthInhibrx Biosciences EPS INBX
Diluted earnings per share by quarter and over the last twelve months, from 2023.
- Last 12 months, to Jun 30, 2026
- −$8.88
- Latest quarter, Q2 FY26
- −$2.34
- Fiscal year 2025
- −$9.04
- −108% on the year before
Inhibrx Biosciences' earnings per share was −$8.88 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$2.34.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$9.04 | −108% |
| FY2024 | $113.78 | n/a |
| FY2023 | −$20.12 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$2.34 | n/a | −$8.88 | |
| Q1 FY26 | −$2.15 | n/a | −$8.39 | |
| Q4 FY25 | −$2.11 | n/a | −$9.04 | |
| Q3 FY25 | −$2.28 | n/a | −$10.02 | |
| Q2 FY25 | −$1.85 | −101% | −$10.58 | |
| Q1 FY25 | −$2.80 | n/a | $116.75 | |
| Q4 FY24 | −$3.09 | n/a | $113.78 | |
| Q3 FY24 | −$2.84 | n/a | $109.94 | |
| Q2 FY24 | $125.48 | n/a | $108.39 | |
| Q1 FY24 | −$5.77 | n/a | −$21.40 | |
| Q4 FY23 | −$6.93 | n/a | −$20.12 | |
| Q3 FY23 | −$4.39 | n/a | n/a |
Against its peers
Companies in Biotechnology nearest Inhibrx Biosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| INBXInhibrx Biosciences | −$8.88 | |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| RGENRepligen | $0.73 | |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| Peer median | $0.71 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Inhibrx Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.